Jeffrey Hung
Stock Analyst at Morgan Stanley
(3.07)
# 1,356
Out of 4,761 analysts
193
Total ratings
42.06%
Success rate
1.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CYTK Cytokinetics | Upgrades: Overweight | $70 → $67 | $50.26 | +33.31% | 13 | Feb 13, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $170 → $185 | $120.69 | +53.29% | 25 | Feb 4, 2025 | |
| PTCT PTC Therapeutics | Upgrades: Overweight | $45 → $67 | $50.69 | +32.18% | 10 | Dec 13, 2024 | |
| FOLD Amicus Therapeutics | Downgrades: Equal-Weight | $17 → $12 | $9.19 | +30.58% | 4 | Dec 13, 2024 | |
| BIOA BioAge Labs | Initiates: Overweight | $40 | $4.50 | +788.89% | 1 | Oct 21, 2024 | |
| ITCI Intra-Cellular Therapies | Maintains: Overweight | $92 → $95 | $128.60 | -26.13% | 5 | Oct 11, 2024 | |
| CNTA Centessa Pharmaceuticals | Upgrades: Overweight | $11 → $26 | $16.63 | +56.34% | 1 | Sep 19, 2024 | |
| ENGN enGene Holdings | Maintains: Overweight | $40 | $6.29 | +535.93% | 2 | Sep 11, 2024 | |
| ACAD ACADIA Pharmaceuticals | Downgrades: Equal-Weight | $28 → $20 | $19.95 | +0.25% | 23 | Aug 7, 2024 | |
| CRVO CervoMed | Initiates: Overweight | $35 | $2.28 | +1,435.09% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $150 | $136.01 | +10.29% | 4 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $70 | $37.46 | +86.87% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $7.59 | +229.38% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $40 | $54.53 | -26.65% | 5 | Apr 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $55 | $27.85 | +97.49% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $0.87 | +359.29% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $13 → $4 | $3.03 | +32.01% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $55 | $56.07 | -1.91% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.77 | +125.99% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $60 → $140 | $4.08 | +3,331.37% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $84 | $42.59 | +97.23% | 7 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $40 | $11.66 | +243.05% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $1.76 | +695.45% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $1.63 | +206.75% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $1.82 | +64.84% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $14 | $1.29 | +985.27% | 7 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $19 | $9.03 | +110.41% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $15 | $1.41 | +963.83% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.68 | +495.24% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $36.85 | -40.30% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $36.91 | +302.33% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $2.62 | +2,190.08% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $4.22 | +42.18% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $54 | $0.72 | +7,369.91% | 6 | May 8, 2020 |
Cytokinetics
Feb 13, 2025
Upgrades: Overweight
Price Target: $70 → $67
Current: $50.26
Upside: +33.31%
Neurocrine Biosciences
Feb 4, 2025
Maintains: Overweight
Price Target: $170 → $185
Current: $120.69
Upside: +53.29%
PTC Therapeutics
Dec 13, 2024
Upgrades: Overweight
Price Target: $45 → $67
Current: $50.69
Upside: +32.18%
Amicus Therapeutics
Dec 13, 2024
Downgrades: Equal-Weight
Price Target: $17 → $12
Current: $9.19
Upside: +30.58%
BioAge Labs
Oct 21, 2024
Initiates: Overweight
Price Target: $40
Current: $4.50
Upside: +788.89%
Intra-Cellular Therapies
Oct 11, 2024
Maintains: Overweight
Price Target: $92 → $95
Current: $128.60
Upside: -26.13%
Centessa Pharmaceuticals
Sep 19, 2024
Upgrades: Overweight
Price Target: $11 → $26
Current: $16.63
Upside: +56.34%
enGene Holdings
Sep 11, 2024
Maintains: Overweight
Price Target: $40
Current: $6.29
Upside: +535.93%
ACADIA Pharmaceuticals
Aug 7, 2024
Downgrades: Equal-Weight
Price Target: $28 → $20
Current: $19.95
Upside: +0.25%
CervoMed
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $2.28
Upside: +1,435.09%
Jul 12, 2024
Maintains: Equal-Weight
Price Target: $160 → $150
Current: $136.01
Upside: +10.29%
May 23, 2024
Maintains: Overweight
Price Target: $50 → $70
Current: $37.46
Upside: +86.87%
Apr 30, 2024
Initiates: Overweight
Price Target: $25
Current: $7.59
Upside: +229.38%
Apr 2, 2024
Maintains: Equal-Weight
Price Target: $75 → $40
Current: $54.53
Upside: -26.65%
Feb 20, 2024
Initiates: Overweight
Price Target: $55
Current: $27.85
Upside: +97.49%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $0.87
Upside: +359.29%
Dec 19, 2023
Downgrades: Underweight
Price Target: $13 → $4
Current: $3.03
Upside: +32.01%
Dec 19, 2023
Upgrades: Overweight
Price Target: $29 → $55
Current: $56.07
Upside: -1.91%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.77
Upside: +125.99%
Dec 8, 2023
Upgrades: Equal-Weight
Price Target: $60 → $140
Current: $4.08
Upside: +3,331.37%
Nov 3, 2023
Maintains: Overweight
Price Target: $90 → $84
Current: $42.59
Upside: +97.23%
Nov 3, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $11.66
Upside: +243.05%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $1.76
Upside: +695.45%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $1.63
Upside: +206.75%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $1.82
Upside: +64.84%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $15 → $14
Current: $1.29
Upside: +985.27%
Feb 3, 2023
Maintains: Overweight
Price Target: $27 → $19
Current: $9.03
Upside: +110.41%
Feb 3, 2023
Upgrades: Overweight
Price Target: $15
Current: $1.41
Upside: +963.83%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.68
Upside: +495.24%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $36.85
Upside: -40.30%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $36.91
Upside: +302.33%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $2.62
Upside: +2,190.08%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $4.22
Upside: +42.18%
May 8, 2020
Maintains: Overweight
Price Target: $58 → $54
Current: $0.72
Upside: +7,369.91%